MOB — Moberg Pharma AB (publ) Income Statement
0.000.00%
Last trade - 00:00
- SEK514.67m
- SEK192.70m
- 37
- 27
- 57
- 32
2019 June 30th | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 6 M | 18 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 15.6 | 50.5 | 0 | 0.207 | 0 |
Cost of Revenue | |||||
Gross Profit | 15.6 | 50.5 | 0 | — | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 19.8 | 34.5 | 19.7 | 20.4 | 27.5 |
Operating Profit | -4.22 | 16 | -19.7 | -20.2 | -27.5 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -5.07 | 13.4 | -20 | -19.5 | -25.4 |
Provision for Income Taxes | |||||
Net Income After Taxes | -4.73 | 10.2 | -16.2 | -15.7 | -21.1 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | 559 | 8.8 | 7.49 | -15.7 | -21.1 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 559 | 8.8 | 7.49 | -15.7 | -21.1 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.48 | 3.36 | -2.41 | -1.38 | -1.33 |
Dividends per Share |